Acarix' share issue well oversubscribed in connection with the initial public offering on Nasdaq First North Premier in Stockholm

Press Release December 8, 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Acarix' share issue well oversubscribed in connection with the initial public offering on Nasdaq First North Premier in Stockholm

Acarix AB ("Acarix" or the "Company") is pleased to announce that it has successfully raised SEK 140 million before transaction costs through a well-oversubscribed share issue in connection with the initial public offering listing on Nasdaq First North Premier (the "Offering"). The Offering was directed to institutional and professional investors as well as to the public in Sweden and Denmark. Due to the large interest, allotment of new shares has been made to around 1,200 new shareholders among 3,000 applicants.

First day of trading of the Company's shares on Nasdaq First North Premier in Stockholm is expected to be December 19, 2016.

Acarix is a Swedish/Danish commercial stage medical device company, specialised in non-invasive, non-radiation acoustic rule-out of Coronary Artery Disease (CAD). The funds raised will primarily be used to execute the Company's commercialization strategy and anticipated launch in Q2, 2017, with initial focus on Germany, UK, Sweden and Denmark for the already CE-marked CADScor^®System.

 

The subscription period for Acarix' Offering expired on December 7, 2016. Already before the subscription period began, a number of existing and new investors, including Puhua Jingxin Guzhou Health Management Partnership, the Bank of Åland's Fund Management Division, Ålandsbanken Abp, Sverker Martin-Löf, Carl-Olof By, and Rolf Börjesson through the company Industrial Development Partners AB, and Lars Holmqvist, former CEO of Dako and later Senior Vice President of Agilent, had committed to subscribe for shares in the Offering totalling just over SEK 120 million or approximately 86 per cent of the Offering. These investors were then given priority when shares were allocated.  However, the overall goal of the Offering remained to obtain a broad distribution of shares among the public in Sweden and Denmark in order to allow regular and liquid trading of Acarix' shares on Nasdaq First North Premier.